Kissei Pharmaceutical Co., Ltd.
Kissei Pharmaceutical Co., Ltd. (KSPHF) Revenue
Annual & quarterly revenue history · segment & region breakdown
KSPHF · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsKissei Pharmaceutical Co., Ltd. trailing twelve-month (TTM) revenue is $97.92B, an increase of 10.97% year-over-year from $98.02B in FY2026.
Revenue trend
2026 – 2007 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2026-03-31 | $98.02B | +$9.69B | +10.97% |
| 2025-03-31 | $88.33B | +$12.75B | +16.87% |
| 2024-03-31 | $75.58B | +$8.09B | +11.98% |
| 2023-03-31 | $67.49B | +$2.11B | +3.23% |
| 2022-03-31 | $65.38B | -$3.66B | -5.31% |
| 2021-03-31 | $69.04B | +$68.46B | +11685.35% |
| 2020-03-31 | $0.59B | -$0.07B | -10.31% |
| 2019-03-31 | $0.65B | -$0.04B | -6.12% |
| 2018-03-31 | $0.70B | +$0.05B | +8.12% |
| 2017-03-31 | $0.64B | +$0.01B | +1.45% |
Compare revenue vs peers
Drug Manufacturers - Specialty & GenericCompare KSPHF revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Kissei Pharmaceutical Co., Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Kissei Pharmaceutical Co., Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in JPY.
Data sourced from Kissei Pharmaceutical Co., Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
KSPHF revenue · 4 questionsKSPHF's trailing twelve-month (TTM) revenue is $97.92B. That is an increase of 10.97% year-over-year from $98.02B in FY2026.
▸ Source: FMP · Kissei Pharmaceutical Co., Ltd. SEC filings · GAAP · Kissei Pharmaceutical Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026